公开(公告)号：EP0778888B1

公开(公告)日：2006-06-21

申请号：EP95927611.4

申请日：1995-08-15

申请人： Sanofi Pasteur Limited

发明人： ROVINSKI, Benjamin ,  CAO, Shi-Xian ,  YAO, Fei-long ,  PERSSON, Roy ,  KLEIN, Michel H.

IPC分类号： C12N7/00 ,  C12N15/62 ,  C12N15/85 ,  C07K14/08 ,  C07K14/11 ,  C07K14/16 ,  C12Q1/68 ,  G01N33/53 ,  G01N33/577 ,  A61K39/12 ,  A61K39/21

CPC分类号： G01N33/56988 ,  A61K39/00 ,  C07K14/005 ,  C07K2319/00 ,  C12N7/00 ,  C12N2740/16023 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2760/16022 ,  C12N2770/00022 ,  G01N2469/20

摘要： Non-infectious, retrovirus-like particles comprise an assembly of an env gene product, a pol gene product and a gag gene product contain an antigenic marker which is non-retroviral or non-HIV retroviral. In one embodiment, the marker comprises an amino acid sequence containing an epitope inserted into the gag gene product at an antigenically-active insertion site. In another embodiment, the marker comprises an antigenic anchor sequence operatively connected to the env gene product replacing endogenous anchoring function. In a further embodiment, the marker comprises modification of an immunodominant region of the env gene product to substantially prevent recognition of the immunodominant region. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis. The presence of the antigenic marker enables recognition that antiserum containing anti-retroviral antibodies has been generated by exposure to the non-infectious retrovirus-like particles by testing for antibodies specific to the antigenic marker.

公开(公告)号：EP1108035B1

公开(公告)日：2007-08-08

申请号：EP99942661.2

申请日：1999-09-03

申请人： Sanofi Pasteur Limited

发明人： GAJEWCZYK, Diane, M. ,  PERSSON, Roy ,  YAO, Fei-Long ,  CAO, Shi-Xian ,  KLEIN, Michel, H. ,  TARTAGLIA, James ,  MOINGEON, Phillipe ,  ROVINSKI, Benjamin

IPC分类号： C12N15/37 ,  C12N15/86 ,  C07K14/025 ,  A61K48/00

CPC分类号： A61B5/055 ,  A61B5/0263 ,  A61B5/029 ,  A61B5/41 ,  A61K48/00 ,  A61K2039/51 ,  A61K2039/53 ,  C07K14/005 ,  C12N2710/20022 ,  C12N2710/20043 ,  Y10S977/804 ,  Y10S977/904 ,  Y10S977/916 ,  Y10S977/924

摘要： Vectors for DNA immunization against cervical cancer comprise a nucleic acid molecule encoding at least one none-toxic T-cell epitope of the E6 and/or E7 antigens of a strain of human papilloma virus (HPV) associated with cervical cancer, such as HPV-16, and a promoter operatively coupled to the nucleic acid molecule for expression of the nucleic acid molecule in a host to which the vector is administered.

公开(公告)号：EP1280551B1

公开(公告)日：2007-01-10

申请号：EP01927532.0

申请日：2001-04-25

申请人： Sanofi Pasteur Limited

发明人： ROVINSKI, Benjamin ,  TARTAGLIA, James ,  CAO, Shi-Xian ,  PERSSON, Roy ,  KLEIN, Michel, H.

IPC分类号： A61K39/12

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55577 ,  C12N2710/24043 ,  C12N2740/16122 ,  C12N2740/16134

摘要： A virus neutralizing level of antibodies to a primary HIV isolate is generated in a host by a prime-boost administration of antigents. The primary antigen is a DNA molecule encoding an envelop glycoprotein of a primary isolate of HIV-1 while the boosting antigen is either a non-infectious, non-replicating HIV-like particle having the envelope glycoprotein of a primary isolate of HIV-1 or an attenuated viral vector expressing an envelope glycoprotein of a primary isolate of HIV-1.